A practical reference on CJC-1295: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
| Property | Value | Notes |
|---|---|---|
| Molecular weight, DAC form | About 3647 Da | Varies with salt form |
| Molecular weight, non-DAC form | About 3358 Da | MOD GRF(1-29) |
| Solubility class | Water soluble | Also dissolves in polar solvents |
| Reported half-life, DAC form | About five to eight days | Values from human studies |
| Common synonyms | CJC-1295; MOD GRF(1-29) | Name depends on variant |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
Although the disease process tends to be slowly progressive over decades, it usually remains asymptomatic until an atheroma ulcerates, leading to immediate blood clotting at the site of the atheroma ulcer. This triggers a cascade of events that leads to clot enlargement, which may quickly obstruct blood flow. A complete blockage leads to ischemia of the myocardial (heart) muscle and damage. This process is the myocardial infarction or "heart attack". If the heart attack is not fatal, fibrous organization of the clot within the lumen ensues, covering the rupture but also producing stenosis or closure of the lumen, or over time and after repeated ruptures, resulting in a persistent, usually localized stenosis or blockage of the artery lumen. Stenoses can be slowly progressive, whereas plaque ulceration is a sudden event that occurs specifically in atheromas with thinner/weaker fibrous caps that have become "unstable". Repeated plaque ruptures, ones not resulting in total lumen closure, combined with the clot patch over the rupture and healing response to stabilize the clot, are the process that produces most stenoses over time. The stenotic areas often become more stable despite increased flow velocities at these narrowings. Most major blood-flow-stopping events occur at large plaques, which, before their rupture, produced little, if any, stenosis. From clinical trials, 20% is the average stenosis at plaques that subsequently rupture, with resulting complete artery closure. Most severe clinical events do not occur at plaques that produce high-grade stenosis.
Weigert's hematoxylin is a sequence of three solutions: ferric chloride in diluted hydrochloric acid, hematoxylin in 95% ethanol, and potassium ferricyanide solution alkalized by sodium borate. It is used to stain the nuclei. Solution A, also called plasma stain, contains acid fuchsin, Xylidine Ponceau, glacial acetic acid, and distilled water. Other red acid dyes can be used, e.g. the Biebrich scarlet in Lillie's trichrome. Solution B contains phosphomolybdic/phosphotungstic acid in distilled water. Solution C, also called fibre stain, contains Light Green SF yellowish, or alternatively Fast Green FCF. It is used to stain collagen. If blue is preferred to green, methyl blue or water blue can be substituted. Standard applications: Masson's trichrome staining is widely used to study muscular pathologies (muscular dystrophy), cardiac pathologies (infarct), hepatic pathologies (cirrhosis) or kidney pathologies (glomerular fibrosis). It can also be used to detect and analyze tumors on hepatic and kidney biopsies.
== Structure == A triple helix is named such because it is made up of three separate helices. Each of these helices shares the same axis, but they do not take up the same space because each helix is translated angularly around the axis. Generally, the identity of a triple helix depends on the type of helices that make it up. For example: a triple helix made of three strands of collagen protein is a collagen triple helix, and a triple helix made of three strands of DNA is a DNA triple helix. As with other types of helices, triple helices have handedness: right-handed or left-handed. A right-handed helix moves around its axis in a clockwise direction from beginning to end. A left-handed helix is the right-handed helix's mirror image, and it moves around the axis in a counterclockwise direction from beginning to end. The beginning and end of a helical molecule are defined based on certain markers in the molecule that do not change easily. For example: the beginning of a helical protein is its N terminus, and the beginning of a single strand of DNA is its 5' end. The collagen triple helix is made of three collagen peptides, each of which forms its own left-handed polyproline helix. When the three chains combine, the triple helix adopts a right-handed orientation. The collagen peptide is composed of repeats of Gly-X-Y, with the second residue (X) usually being Pro and the third (Y) being hydroxyproline.
The discoverers proposed the name "Prometheum" (sic; the spelling was subsequently changed), derived from Prometheus, the Titan in Greek mythology who stole fire from Mount Olympus and brought it down to humans, to symbolize "both the daring and the possible misuse of mankind's intellect". A sample of the metal was made only in 1963. The two sources of natural promethium are rare alpha decays of natural europium-151 (producing promethium-147) and spontaneous fission of uranium (various isotopes). Promethium-145 is the most stable promethium isotope, but the only isotope with practical applications is promethium-147, chemical compounds of which are used in luminous paint, atomic batteries and thickness-measurement devices. Because natural promethium is exceedingly scarce, it is typically synthesized by bombarding uranium-235 (enriched uranium) with thermal neutrons to produce promethium-147 as a fission product.
Sources: en.wikipedia.org
=== Surgery === Corneal transplant surgery may be difficult due to the peripheral thinning of the cornea, even with large and off-center grafts. Therefore, surgery is usually reserved for people that do not tolerate contact lenses. Several different surgical approaches may be taken, and no one approach is currently established as the standard. Examples of surgical procedures used for PMD include: wedge resection, lamellar crescentic resection, penetrating keratoplasty, lamellar keratoplasty, epikeratoplasty and intracorneal segments. Transplantation of the entire thickness of the cornea (penetrating keratoplasty) may be performed if there is enough normal tissue present. However, if there is not enough normal tissue present, then attaching the graft is difficult. New surgical techniques are in evaluation such as Intrastromal lamellar Keratoplasties and Sclerocorneal Intrastromal Lamellar Keratoplasty (SILK), these techniques allow thickening of the inferior peripheral cornea and steepening of the vertical meridien. Due to the thinning of the cornea, people with PMD are poor candidates for procedures such as LASIK and photorefractive keratectomy.
Arthritis – Types – Fibromyalgia by the CDC Fibromyalgia by the National Institute of Arthritis and Musculoskeletal and Skin Diseases Fibromyalgia by the American College of Rheumatology Fibromyalgia by the NHS
== Molecular origins == Momentum transport in gases is mediated by discrete molecular collisions, and in liquids by attractive forces that bind molecules close together. Because of this, the dynamic viscosities of liquids are typically much larger than those of gases. In addition, viscosity tends to increase with temperature in gases and decrease with temperature in liquids. Above the liquid-gas critical point, the liquid and gas phases are replaced by a single supercritical phase. In this regime, the mechanisms of momentum transport interpolate between liquid-like and gas-like behavior. For example, along a supercritical isobar (constant-pressure surface), the kinematic viscosity decreases at low temperature and increases at high temperature, with a minimum in between. Kostya Trachenko and Vadim Brazhkin provided a rough estimate for the value at the minimum, given by
Hertz (1939), operations research scholar known for pioneering the Monte Carlo methods in finance Victor Wouk (1939), pioneer in the development of electric and hybrid vehicles Julius Ashkin (1940), nuclear physicist, brother of Arthur Ashkin '47 Jeremiah Stamler (1940), epidemiologist, expert in the field of preventive cardiology, professor emeritus at Northwestern University Ulrich P. Strauss (1941), chemist at Rutgers University, 1971 Guggenheim Fellow Bruce Wallace (1941), geneticist, professor at Virginia Tech Robert S. Wallerstein (1941), psychoanalyst and former president of the International Psychoanalytical Association and director of the Langley Porter Psychiatric Institute, brother of political scientist Immanuel Wallerstein '51 Kimball Chase Atwood III (1942), geneticist, professor at Columbia University Medical School Leon Davidson (1942), chemical engineer known for his work in the Manhattan Project and the study of Unidentified Flying Objects Karl Koopman (1943), chiropterologist and curator at the American Museum of Natural History Robert G.
=== Blood group systems === Red blood cell membranes consist of a phospholipid bilayer, littered with proteins, lipids, carbohydrates, and combinations of these substances. These substances are called antigens because they stimulate an immune response when an individual is exposed to the substance, but the exposed individual does not carry nor express the genes which encode said antigens. Each individual has a unique genetic and phenotypic makeup of antigens, much like the dermatoglyphics of human fingerprints. As of 2023, there are 44 blood group systems, each containing several red blood cell antigens totaling 354, determined by approximately 49 separate genes. Of these antigens, only a handful are considered clinically significant, meaning that they can stimulate the production of antibodies capable of causing red cell hemolysis. This is particularly important for the transfusion of packed red blood cells and other cellular blood products. Examples of blood group systems that contain antigens capable of inducing clinically significant alloantibodies (antibodies against non-self antigens) include, but are not limited to the ABO, Rh, Kell, Duffy, Kidd, and MNS blood group systems.
Sources: en.wikipedia.org
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.
The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.
The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.